Chapter 2: Management of geriatric diseases and geriatric syndrome using comprehensive geriatric assessment (CGA): English translation of the Japanese CGA-based healthcare guidelines 2024

IF 2.4 4区 医学 Q3 GERIATRICS & GERONTOLOGY
Hiroyuki Umegaki, Shosuke Satake, Sinya Ishii, Taro Kojima, Hiroshi Akasaka, Sumito Ogawa, Satoru Ebihara, Yukari Tsubata, Masahiro Akishita
{"title":"Chapter 2: Management of geriatric diseases and geriatric syndrome using comprehensive geriatric assessment (CGA): English translation of the Japanese CGA-based healthcare guidelines 2024","authors":"Hiroyuki Umegaki,&nbsp;Shosuke Satake,&nbsp;Sinya Ishii,&nbsp;Taro Kojima,&nbsp;Hiroshi Akasaka,&nbsp;Sumito Ogawa,&nbsp;Satoru Ebihara,&nbsp;Yukari Tsubata,&nbsp;Masahiro Akishita","doi":"10.1111/ggi.15087","DOIUrl":null,"url":null,"abstract":"<p>Is CGA effective in frail older adults?</p><p><b>Statement: CGA is proposed to be performed on frail older adults</b>.</p><p>Strength of evidence D.</p><p>Degree of recommendation 2 (weak) (agreement rate: 100%).</p><p>Are evaluations with assessment tools for “cognitive function” and “behavioral and psychological symptom (BPSD)” effective in the CGA for older adults with dementia?</p><p><b>Statement: The use of assessment tools of cognitive function or BPSD is recommended when performing CGA on older adults with dementia</b>.</p><p>Strength of evidence C.</p><p>Degree of recommendation 1 (strong) (agreement rate: 88.9%).</p><p>Is CGA effective for older patients with polypharmacy?</p><p><b>Statement: Conducting CGA is proposed for older patients with polypharmacy</b>.</p><p>Strength of evidence B.</p><p>Degree of recommendation 2 (weak) (agreement rate: 68.9%).</p><p>Is CGA effective for older patients with multimorbidity?</p><p><b>Statement: Performing CGA is recommended for older patients with multimorbidity</b>.</p><p>Strength of evidence B.</p><p>Degree of recommendation 1 (strong) (agreement rate: 77.8%).</p><p>Is it effective to use CGA in the management of older patients with DM?</p><p><b>Statement: CGA is proposed in the management of older patients with DM</b>.</p><p>Strength of evidence D.</p><p>Degree of recommendation 2 (weak) (agreement rate: 100%).</p><p>Is it effective to use CGA to evaluate older adults with hypertension or heart disease to determine a treatment plan?</p><p><b>Statement: CGA is proposed to evaluate older adults with hypertension or heart disease to determine a treatment plan</b>.</p><p>Strength of evidence C.</p><p>Degree of recommendation 2 (weak) (agreement rate: 91.7%).</p><p>Is a multidisciplinary team approach based on CGA effective for treating pneumonia in older patients?</p><p><b>Statement: Regarding the effectiveness of a multidisciplinary team approach based on CGA for older patients with pneumonia, no evidence showed direct effects, but a multidisciplinary team approach that comprehensively understands the characteristics of older patients based on CGA is important, and we look forward to future research</b>.</p><p>Is CGA screening effective for managing fractures in older adults?</p><p><b>Statement: Performing CGA is recommended in the management of older patients after fracture</b>.</p><p>Strength of evidence B.</p><p>Degree of recommendation 1 (strong) (agreement rate: 90%).</p><p>Is it effective to use CGA to evaluate patients before surgery for gastrointestinal cancer, aortic disease, or heart disease in older adults?</p><p><b>Statement: Evaluation using CGA before surgery for gastrointestinal cancer, aortic disease, or heart disease in older patients is recommended</b>.</p><p>Strength of evidence B.</p><p>Degree of recommendation 1 (strong) (agreement rate: 88.9%).</p><p>Is CGA effective in managing malignant tumors (systematic cancer therapy) in older patients?</p><p><b>Statement: CGA is recommended in the management of older patients with malignant tumors who are scheduled for systematic cancer therapy</b>.</p><p>Strength of evidence A.</p><p>Degree of recommendation 1 (strong) (agreement rate: 100%).</p><p>HU received research funding from the following companies: Astellas Pharma, Abbott Japan, Eisai, MSD, Otsuka Pharmaceutical, ONO, Sanofi, Daiichi Sankyo, Sumitomo Pharma, Takeda, Mitsubishi Tanabe Pharma Chugai Pharmaceutical, Tsumura, Pfizer Japan., Fujifilm RI Pharma, Toyama Chemical., and Mochida Pharmaceutical. IS received research funding from Sompo Care. KT received honoraria from Pfizer Japan. <b>S</b>O received honoraria from Daiichi Sankyo. YT received honoraria from AstraZeneca, Kyowa Kirin, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb. MA received research funding from Astellas Pharma, Bayer Yakuhin, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Merck &amp; Co., Fukuda Lifetech, Mitsubishi-Tanabe Pharma, Ono Pharmaceutical, Takeda, and Tsumura, and lecture fees from Daiichi Sankyo, Merck &amp; Co., Toa Eiyo, and Towa Pharmaceutical. The other authors declare no conflict of interest.</p>","PeriodicalId":12546,"journal":{"name":"Geriatrics & Gerontology International","volume":"25 S1","pages":"16-23"},"PeriodicalIF":2.4000,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ggi.15087","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Geriatrics & Gerontology International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ggi.15087","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Is CGA effective in frail older adults?

Statement: CGA is proposed to be performed on frail older adults.

Strength of evidence D.

Degree of recommendation 2 (weak) (agreement rate: 100%).

Are evaluations with assessment tools for “cognitive function” and “behavioral and psychological symptom (BPSD)” effective in the CGA for older adults with dementia?

Statement: The use of assessment tools of cognitive function or BPSD is recommended when performing CGA on older adults with dementia.

Strength of evidence C.

Degree of recommendation 1 (strong) (agreement rate: 88.9%).

Is CGA effective for older patients with polypharmacy?

Statement: Conducting CGA is proposed for older patients with polypharmacy.

Strength of evidence B.

Degree of recommendation 2 (weak) (agreement rate: 68.9%).

Is CGA effective for older patients with multimorbidity?

Statement: Performing CGA is recommended for older patients with multimorbidity.

Strength of evidence B.

Degree of recommendation 1 (strong) (agreement rate: 77.8%).

Is it effective to use CGA in the management of older patients with DM?

Statement: CGA is proposed in the management of older patients with DM.

Strength of evidence D.

Degree of recommendation 2 (weak) (agreement rate: 100%).

Is it effective to use CGA to evaluate older adults with hypertension or heart disease to determine a treatment plan?

Statement: CGA is proposed to evaluate older adults with hypertension or heart disease to determine a treatment plan.

Strength of evidence C.

Degree of recommendation 2 (weak) (agreement rate: 91.7%).

Is a multidisciplinary team approach based on CGA effective for treating pneumonia in older patients?

Statement: Regarding the effectiveness of a multidisciplinary team approach based on CGA for older patients with pneumonia, no evidence showed direct effects, but a multidisciplinary team approach that comprehensively understands the characteristics of older patients based on CGA is important, and we look forward to future research.

Is CGA screening effective for managing fractures in older adults?

Statement: Performing CGA is recommended in the management of older patients after fracture.

Strength of evidence B.

Degree of recommendation 1 (strong) (agreement rate: 90%).

Is it effective to use CGA to evaluate patients before surgery for gastrointestinal cancer, aortic disease, or heart disease in older adults?

Statement: Evaluation using CGA before surgery for gastrointestinal cancer, aortic disease, or heart disease in older patients is recommended.

Strength of evidence B.

Degree of recommendation 1 (strong) (agreement rate: 88.9%).

Is CGA effective in managing malignant tumors (systematic cancer therapy) in older patients?

Statement: CGA is recommended in the management of older patients with malignant tumors who are scheduled for systematic cancer therapy.

Strength of evidence A.

Degree of recommendation 1 (strong) (agreement rate: 100%).

HU received research funding from the following companies: Astellas Pharma, Abbott Japan, Eisai, MSD, Otsuka Pharmaceutical, ONO, Sanofi, Daiichi Sankyo, Sumitomo Pharma, Takeda, Mitsubishi Tanabe Pharma Chugai Pharmaceutical, Tsumura, Pfizer Japan., Fujifilm RI Pharma, Toyama Chemical., and Mochida Pharmaceutical. IS received research funding from Sompo Care. KT received honoraria from Pfizer Japan. SO received honoraria from Daiichi Sankyo. YT received honoraria from AstraZeneca, Kyowa Kirin, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Bristol-Myers Squibb. MA received research funding from Astellas Pharma, Bayer Yakuhin, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Merck & Co., Fukuda Lifetech, Mitsubishi-Tanabe Pharma, Ono Pharmaceutical, Takeda, and Tsumura, and lecture fees from Daiichi Sankyo, Merck & Co., Toa Eiyo, and Towa Pharmaceutical. The other authors declare no conflict of interest.

第2章:使用综合老年病评估(CGA)管理老年病和老年综合征:日本基于CGA的医疗保健指南2024的英文翻译
CGA对体弱老年人有效吗?声明:建议对体弱的老年人进行CGA。d .推荐程度2(弱)(一致性:100%)。使用“认知功能”和“行为和心理症状(BPSD)”的评估工具对老年痴呆患者的CGA有效吗?声明:在对老年痴呆患者进行CGA时,建议使用认知功能评估工具或BPSD。证据强度c .推荐程度1(强)(一致性:88.9%)。CGA对老年多药患者有效吗?声明:建议对老年多药患者进行CGA。证据强度b .推荐程度2(弱)(一致性:68.9%)。CGA对老年多病患者有效吗?声明:推荐对老年多病患者行CGA。证据强度b .推荐程度1(强)(一致性:77.8%)。CGA在老年糖尿病患者的治疗中是否有效?结论:CGA可用于老年dm患者的治疗。证据强度d。推荐程度2(弱)(符合率100%)。使用CGA评估老年人高血压或心脏病以确定治疗方案是否有效?声明:CGA被建议用于评估患有高血压或心脏病的老年人,以确定治疗计划。证据强度c .推荐程度2(弱)(一致性:91.7%)。基于CGA的多学科团队治疗老年肺炎有效吗?声明:关于基于CGA的多学科团队方法治疗老年肺炎患者的有效性,目前尚无证据显示直接效果,但基于CGA全面了解老年患者特征的多学科团队方法很重要,我们期待未来的研究。CGA筛查对老年人骨折有效吗?结论:在老年患者骨折后的治疗中推荐使用CGA。b .推荐程度1(强)(一致性:90%)。CGA在老年人胃肠癌、主动脉疾病或心脏病术前评估患者是否有效?声明:推荐在胃肠癌、主动脉疾病或老年心脏病患者术前使用CGA进行评估。b .推荐程度1(强)(一致性:88.9%)。CGA对老年患者的恶性肿瘤(系统性癌症治疗)是否有效?声明:CGA被推荐用于计划接受系统癌症治疗的老年恶性肿瘤患者的管理。证据强度a .推荐程度1(强)(一致性:100%)。胡获得了以下公司的研究资助:安斯泰来制药、雅培日本、卫材、默沙东、大冢制药、ONO、赛诺菲、第一三共、住友制药、武田、三菱田边制药、中盖制药、津村制药、辉瑞日本。富士RI制药,富山化学。以及茂田制药。IS得到了Sompo Care的研究资助。KT收到了辉瑞日本公司的酬金。SO收到Daiichi Sankyo的酬金。YT收到了来自阿斯利康、协和麒麟、第一三共、大湖制药、武田制药、中盖制药、百时美施贵宝的酬金。MA获得了来自安斯泰来制药、拜耳雅库欣、中盖制药、第一三共、卫材、默克公司的研究资助;公司、福田生命科技、三菱田边制药、小野制药、武田和津村,以及第一三共、默克公司的演讲费;公司,Toa Eiyo和Toa Pharmaceutical。其他作者声明没有利益冲突。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.50
自引率
6.10%
发文量
189
审稿时长
4-8 weeks
期刊介绍: Geriatrics & Gerontology International is the official Journal of the Japan Geriatrics Society, reflecting the growing importance of the subject area in developed economies and their particular significance to a country like Japan with a large aging population. Geriatrics & Gerontology International is now an international publication with contributions from around the world and published four times per year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信